Exelixis Inc.

02/15/2025 | Press release | Distributed by Public on 02/15/2025 10:10

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.